Alert

Recommended Alerts

Sign Up For Alerts

Patent/PTAB Litigation Changes in Senator Leahy’s “Restoring the America Invents Act”

In 2011, Congress passed the Leahy-Smith America Invents Act (the “AIA”), implementing the most significant reformation to the U.S. patent system in over fifty years. Among the many changes of the AIA was the creation of the Patent Trial and Appeal Board (the “PTAB”). The PTAB serves as the judicial body of the United States Patent and Trademark Office (the “USPTO”) that adjudicates AIA trial proceedings of challenged patents. A decade later, one of the AIA’s namesakes, Senator Patrick Leahy – VT (D), is seeking to recalibrate practices that have evolved due to recent court decisions and PTAB directives that he sees as contrary to goals of the original AIA legislation. As such, Senator Leahy has introduced a new bill entitled the “Restoring the America Invents Act.”

Read More

The UK to Ratify the Unified Patent Court Agreement


Time to Read: 1 minutes Practices: Intellectual Property, Intellectual Property Litigation, Intellectual Property Transactions, Securities & Public Companies, Technology, Media & Telecommunications, Patent Strategy

Printer-Friendly Version

The UK government announced on November 28, 2016 that it will proceed to ratify the Unified Patent Court Agreement (UPCA). The announcement comes after months of uncertainty over the future of the UPCA following the UK’s vote in June to exit the EU (Brexit). The purpose of the UPCA is to establish a single unified court (Unified Patent Court) with exclusive jurisdiction over patent enforcement and validity actions in all contracting states. The UK plays a key role in the current form of the UPCA. For the UPCA to come into effect, 13 states of the EU (including the UK, Germany, and France) must ratify the UPC Agreement. So far, eleven states have ratified, including France. Germany, the UK, and several other EU states were expected to ratify in the spring of 2016 before the Brexit vote threw the feasibility of the UPCA in question. The UK is also designated to be the seat of the Life Science/Chemistry branch of the central division of the Unified Patent Court. The UK’s ratification of the current agreement will pave the way for the UPCA to proceed with minimal delays.

However, questions remain about the UK’s post-Brexit role in the UPC. In its current form, the UPCA restricts participation to member states of the EU. The Court of Justice of the European Union (CJEU) previously issued a decision ruling against participation by non-EU members in an earlier draft of the agreement. However, the decision was opaque in its reasoning, and it remains unclear whether the CJEU would relax the membership requirement to allow participation by the UK post-Brexit, or whether the UK will be able to negotiate around this requirement. Moreover, in its current form, the UPCA elevates EU patent law over national (UK) patent law, an aspect that is likely to be a sore point during negotiations. In announcing the decision, UK Minister of State for Intellectual Property, Baroness Neville Rolfe, noted that “the decision to proceed with ratification should not be seen as pre-empting the UK’s objectives or position in the forthcoming negotiations with the EU.”

Following the announcement, the UK will continue working with the Preparatory Committee for ratification over the coming months. A link to the decision can be found here.

Please see our FAQ for additional information.

Printer-Friendly Version

Cookie Settings